KRAS and non-small cell lung carcinoma: ,4 Using an existing real-world data set of patients diagnosed with NSCLC in 2019 in the Netherlands,5 we examined whether differences in survival pattern on the basis of KRAS/TP53 mutational status could be observed in the entire population of patients with metastatic NSCLC who were treated with first-line immunotherapy, either as monotherapy or in combination with chemotherapy.